A5101693113- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Viral Infectious Diseases and Gene Expression in Insects
- Chronic Lymphocytic Leukemia Research
- Integrated Circuits and Semiconductor Failure Analysis
- Acute Lymphoblastic Leukemia research
- Autoimmune and Inflammatory Disorders Research
- Renal cell carcinoma treatment
- Beetle Biology and Toxicology Studies
- Insect Resistance and Genetics
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- Adolescent and Pediatric Healthcare
- Immune Cell Function and Interaction
- Immune cells in cancer
- Biomedical Ethics and Regulation
- Tuberous Sclerosis Complex Research
Mayo Clinic
2022-2025
Peking University
2024
WinnMed
2022-2024
Kaohsiung Medical University Chung-Ho Memorial Hospital
2024
Kaohsiung Medical University
2024
Mayo Clinic in Arizona
2008-2021
Abstract Cytopenias represent the most common side effect of CAR T-cell therapy (CAR-T) and can predispose for severe infectious complications. Current grading systems, such as Common Terminology Criteria Adverse Events (CTCAE), neither reflect unique quality post–CAR-T neutrophil recovery, nor do they inherent risk infections due to protracted neutropenia. For this reason, a novel EHA/EBMT consensus was recently developed Immune Effector Cell-Associated HematoToxicity (ICAHT). In...
ZUMA-12 is a multicenter phase 2 study that evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, as part of first-line treatment in patients with high-risk large B-cell lymphoma (LBCL). In the primary efficacy analysis (n=37; 15.9 months median follow-up), axi-cel demonstrated high rate complete responses (CR; 78%) and safety profile consistent prior experience. Here, we assessed updated outcomes from 40 treated after ≥3 years...
Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory large B-cell lymphoma (R/R LBCL). Emerging evidence indicates that delayed CAR infusion, including prolonged time from leukapheresis to known as vein-to-vein (V2Vt), may adversely impact clinical outcomes. We conducted a systematic literature review (SLR) meta-analysis identify differences in V2Vt patients...
A 67-year-old post-menopausal woman presented with increased abdominal girth, pain, urinary frequency, and vaginal bleeding. Abdominal CT showed a 17 cm right ovarian multiloculated cystic mass, 6.5 left uterine myomas. The patient underwent total hysterectomy